CA2400784A1 - Therapeutic product, use and formulation thereof - Google Patents

Therapeutic product, use and formulation thereof Download PDF

Info

Publication number
CA2400784A1
CA2400784A1 CA002400784A CA2400784A CA2400784A1 CA 2400784 A1 CA2400784 A1 CA 2400784A1 CA 002400784 A CA002400784 A CA 002400784A CA 2400784 A CA2400784 A CA 2400784A CA 2400784 A1 CA2400784 A1 CA 2400784A1
Authority
CA
Canada
Prior art keywords
therapeutic
formulation
dosage form
therapeutic product
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002400784A
Other languages
French (fr)
Other versions
CA2400784C (en
Inventor
Edward M. Rudnic
James D. Isbister
Donald J. Treacy, Jr.
Sandra E. Wassink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2400784A1 publication Critical patent/CA2400784A1/en
Application granted granted Critical
Publication of CA2400784C publication Critical patent/CA2400784C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

A therapeutic product comprising: a first therapeutic dosage form, a second therapeutic dosage form, and a third therapeutic dosage form, each of said first, second and third therapeutic dosage forms comprising at least one therapeutic agent and a pharmaceutically acceptable carrier, said three dosage forms having different release profiles, said therapeutic product reaching a C max in less than about twelve hours wherein said therapeutic is an antibiotic, an anti-fungal, an anti-viral or an anti-neoplastic agent.
CA002400784A 2000-02-24 2001-02-22 Therapeutic product, use and formulation thereof Expired - Lifetime CA2400784C (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US18454600P 2000-02-24 2000-02-24
US60/184,546 2000-02-24
US68723700A 2000-10-13 2000-10-13
US68722900A 2000-10-13 2000-10-13
US68723500A 2000-10-13 2000-10-13
US68723600A 2000-10-13 2000-10-13
US09/687,237 2000-10-13
US09/687,236 2000-10-13
US09/687,229 2000-10-13
US09/687,235 2000-10-13
PCT/US2001/005758 WO2001062229A1 (en) 2000-02-24 2001-02-22 Therapeutic product, use and formulation thereof

Publications (2)

Publication Number Publication Date
CA2400784A1 true CA2400784A1 (en) 2001-08-30
CA2400784C CA2400784C (en) 2009-05-19

Family

ID=27539122

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002400784A Expired - Lifetime CA2400784C (en) 2000-02-24 2001-02-22 Therapeutic product, use and formulation thereof

Country Status (5)

Country Link
EP (1) EP1257255A4 (en)
JP (2) JP2003523378A (en)
AU (1) AU2001239838A1 (en)
CA (1) CA2400784C (en)
WO (1) WO2001062229A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
AR034813A1 (en) † 2001-07-20 2004-03-17 Novartis Ag PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
CA2465405A1 (en) * 2001-11-02 2003-05-08 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
DE50105577D1 (en) * 2001-12-21 2005-04-14 Biopartners Gmbh Baar RIBAVIRIN GRANULATE FOR THE MANUFACTURE OF FILM TABLETS
CZ298224B6 (en) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Pharmaceutical composition containing ribavirin as active substance and process for its preparation
JP2006528185A (en) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション Antibiotic preparations, their use and preparation
EP1648407A4 (en) * 2003-07-21 2011-08-31 Middlebrook Pharmaceuticals Inc Antibiotic product, use and formulation thereof
EP1648415A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Antibiotic product, use and formulation thereof
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
US7348144B2 (en) * 2003-08-13 2008-03-25 Agilent Technologies, Inc. Methods and system for multi-drug treatment discovery
EP1658034A4 (en) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc Antibiotic product, use and formulation thereof
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
EP1978940B1 (en) * 2006-01-19 2010-12-29 Dow Global Technologies Inc. Biologically active composition comprising ethylcellulose
CA2635606A1 (en) * 2006-12-04 2008-06-12 Advancis Pharmaceutical Corporation Modified release amoxicillin products
EP2197424A2 (en) * 2007-10-17 2010-06-23 Pharmathen S.A. Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL64009A (en) * 1980-10-31 1984-09-30 Rech Applications Therap Crystalline 1,1-dioxopenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate tosylate hydrates,their production and pharmaceutical compositions containing them
JPS601128A (en) * 1983-06-15 1985-01-07 Shionogi & Co Ltd Long-acting cefaclor preparation
JPS61210025A (en) * 1985-03-14 1986-09-18 Teisan Seiyaku Kk Stabilized antibioitc complex granule preparation
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
DK469989D0 (en) * 1989-09-22 1989-09-22 Bukh Meditec PHARMACEUTICAL PREPARATION
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
EP0804174A4 (en) * 1993-07-21 1998-09-09 Univ Kentucky Res Found A multicompartment hard capsule with control release properties
US5827531A (en) * 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
DE19718012C1 (en) * 1997-04-29 1998-10-08 Jenapharm Gmbh Process for the production of orally applicable solid pharmaceutical forms with controlled release of active substances
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system

Also Published As

Publication number Publication date
EP1257255A1 (en) 2002-11-20
JP2003523378A (en) 2003-08-05
JP5377465B2 (en) 2013-12-25
JP2012001528A (en) 2012-01-05
CA2400784C (en) 2009-05-19
EP1257255A4 (en) 2008-07-30
AU2001239838A1 (en) 2001-09-03
WO2001062229A1 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
CA2400784A1 (en) Therapeutic product, use and formulation thereof
CA2395333A1 (en) Hydrogel-driven drug dosage form
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
CA2231194A1 (en) Pharmaceutical formulation
CA2494015A1 (en) Antibiotic product, use and formulation thereof
WO2001035941A8 (en) Novel composition based on a thiazolidinedione and metformin and use
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
AU3879297A (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
WO2000061115A3 (en) Pharmaceutical formulation comprising amoxycillin
CA2315261A1 (en) Oral pharmaceutical extended release dosage form
CA2333869A1 (en) Mousse composition
WO1996040086A3 (en) Compositions and methods for topical administration of pharmaceutically active agents
WO2000061116A3 (en) Pharmaceutical formulation comprising amoxycillin and clavulanate
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
CA2321826A1 (en) Pharmaceutical formulations of taxanes
WO2004013153A3 (en) Macrolide compounds endowed with antiinflammatory activity
CA2380087A1 (en) Beta-carboline drug products
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
CA2332876A1 (en) Efavirenz compressed tablet formulation
CA2211802A1 (en) Pharmaceutical composition for the treatment of herpes
IL159217A0 (en) An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
MY128896A (en) Pharmaceutical combinations
WO2001035940A3 (en) Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
CA2401191A1 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
AU2000255628A1 (en) Formulation comprising thymol useful in the treatment of drug resistant bacterial infections

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210222